Brenus Pharma

Brenus Pharma is a biotech startup founded in 2019 and headquartered in France. The company's mission is to address the challenge of cancer recurrence, a significant issue for solid tumors, through the development of a next-generation cancer treatment leveraging an "off-the-shelf" therapeutic platform. Their lead candidate focuses on colorectal cancer, the second deadliest cancer globally, and aims to educate the immune system more effectively than existing therapies. Brenus Pharma has been recognized for its efforts, winning the "Best Biotech Startup" award in 2024. Recently, the company secured a $25M Series A investment on 18 September 2024 from a group of prominent investors, including Angelor, UI Investissement, INVESTSUD, Crédit Agricole Centre-Est, Stephane Legastelois, Meusinvest (Noshaq), and Jacques Gardette. This investment will enable Brenus Pharma to accelerate its clinical development and pursue clinical collaborations, potentially setting a new paradigm in oncology by empowering patients to combat their diseases.